Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.79
-0.12 (-1.35%)
At close: Aug 13, 2025, 4:00 PM
8.80
+0.01 (0.11%)
Pre-market: Aug 14, 2025, 8:43 AM EDT
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $140.90M in the quarter ending June 30, 2025, a decrease of -44.68%. This brings the company's revenue in the last twelve months to $851.60M, down -22.74% year-over-year. In the year 2024, Emergent BioSolutions had annual revenue of $1.04B, down -0.54%.
Revenue (ttm)
$851.60M
Revenue Growth
-22.74%
P/S Ratio
0.56
Revenue / Employee
$946,222
Employees
900
Market Cap
468.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EBS News
- 1 day ago - Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
- 6 days ago - Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Emergent BioSolutions Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 17 days ago - Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - GlobeNewsWire
- 17 days ago - New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - GlobeNewsWire